Placebo News and Research

RSS

First study to show cost-effectiveness of pre-diabetes intervention

More than 40 million Americans face a high risk of developing Type 2 diabetes, and it would cost a lot to give all of them intensive help with diet and exercise, or medication, to keep them from developing diabetes.

28 Feb 2005

Finasteride prevents prostate cancer

Recent finding show lives could be saved if men are given the drug Finasteride to prevent prostate cancer. New analysis of data from the Prostate Cancer Prevention Trial in the current issue of CANCER confirms this view. These results represent a milestone in cancer research, showing that prostate cancer could be prevented through drugs.

28 Feb 2005

New compounds for the treatment of HIV/AIDS

Scientists from Tibotec Pharmaceuticals Ltd. presented data on several new compounds for the treatment of HIV/AIDS at the 12th Conference on Retroviruses and Opportunistic Infections (CROI), held February 22-25 in Boston, MA, USA.

27 Feb 2005

Gel provides protection from HIV and herpes

Mount Sinai School of Medicine researchers demonstrated that a gel applied in the vagina provides protection from both the human immunodeficiency virus (HIV) and the herpes simplex Virus. The study, presented at the 12th Conference on Retroviruses and Opportunistic Infections, is the first to show that a gel can retain anti-viral activity within the human vagina.

27 Feb 2005

New imaging technology may serve as objective outcome measures for orthopedic conditions

New imaging technologies are enabling doctors to not only diagnose a variety of orthopaedic and musculoskeletal conditions with more accuracy, but also to determine with unprecedented precision whether clinical recovery from bone, joint or tendon damage is actually complete and not simply a "placebo effect."

27 Feb 2005

Second-generation Antidepressants

A recent article in the prestigious British Medical Journal seems to confirm an increased risk for suicidal behavior among adults taking popular antidepressants. This follows evidence that certain selective serotonin reuptake inhibitors (SSRIs) may have a similar effect among children and adolescents.

27 Feb 2005

Proof that vaccinating children against influenza in the hope of reducing disease spread is inconclusive

Proof that vaccinating children aged 6 to 24 months against influenza in the hope of reducing disease spread is inconclusive. These conclusions are based on a small number of studies based on a large dataset of reasonable quality.

27 Feb 2005

Genzyme begins gene transfer trial for peripheral arterial disease

Genzyme Corporation announced today that the first patient has been treated in a new phase 2 clinical trial examining the safety and effectiveness of locally delivered gene transfer for patients with peripheral arterial disease.

24 Feb 2005

Trial results on the use of recombinant activated factor VII in acute intracerebral haemorrhage

The New England Journal of Medicine (NEJM) today reports positive results from the recently completed clinical trial of recombinant activated factor VII (NovoSeven/rFVIIa) in intracerebral haemorrhage (ICH).

24 Feb 2005

FDA approves Atacand (candesartan cilexetil) for the treatment of heart failure

AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved its angiotensin receptor blocker (ARB) Atacand (candesartan cilexetil) Tablets for the treatment of heart failure (NYHA class II-IV and ejection fraction less than or equal to 40%) to reduce the risk of death from cardiovascular causes and reduce hospitalizations for heart failure.

23 Feb 2005

Short-term use of selective COX-2 inhibitors may be safe for patients with cirrhosis of the liver

Short-term use of selective COX-2 inhibitors may be safe for patients with cirrhosis of the liver, according to a recent study that compared the effects of celecoxib, naproxen, and a placebo on cirrhotic patients in a double-blind randomized controlled study.

22 Feb 2005

First study to explore the use of biofeedback as a complementary treatment to asthma medication

For the estimated 20.3 million adults and 6.3 million children in the U.S. who suffer from asthma, the primary treatment is the use of medications to help reduce the underlying inflammation in the airways.

22 Feb 2005

Increased risk of urinary incontinence with hormone therapy

Menopausal hormone therapy (MHT), consisting of oral estrogen plus progestin or estrogen alone, considered in the past as treatment for urinary incontinenc, was until recently, credited with many benefits well beyond the indications for symptomatic relief of hot flashes, night sweats, and vaginal dryness. One of the benefits of MHT was to improve the symptoms of urinary incontinence (UI), and it has often been prescribed to treat UI.

21 Feb 2005

Stop-smoking products increase quit rate for smokers who need to quit the most

An article in the current issue of the Journal of Substance Abuse Treatment (Volume 28, Issue 1, 2005) provides new hope for smokers who are highly dependent upon tobacco and who smoke more than two packs per day.

21 Feb 2005

Biologic therapies are changing the way dermatologists treat psoriasis

Recently approved and investigational biologic therapies are changing the way dermatologists treat psoriasis, a chronic disease that physically and emotionally challenges 4.5 million Americans. As more research is conducted into the effectiveness of these biologics, they are showing great promise for improving the health and well-being of patients with psoriasis.

20 Feb 2005

Quetiapine speeds up rate of decline in Alzheimers

Quetiapine, a drug commonly used in nursing homes to treat agitation and related symptoms in people with Alzheimers' disease actually worsens patients' illness, speeding up their rate of decline significantly, says a paper published on bmj.com.

20 Feb 2005

Antidepressant drugs may be associated with an increased risk of suicidal behaviour

Antidepressant drugs may be associated with an increased risk of suicidal behaviour, particularly in the early stages of treatment, shows new evidence in this week's BMJ.

20 Feb 2005

Olmesartan improves blood supply to kidneys

How do medications that block the renin-angiotensin system (RAS blockers) work to protect against kidney disease in people with diabetes? At least partly by improving the blood supply to the kidneys, suggests a study in the April Journal of the American Society of Nephrology.

17 Feb 2005

Vioxx doubles risk of heart attacks and strokes

The largest prospective trial ever examining the anti-inflammatory drug Vioxx as a chemoprevention agent found that the risk of developing a cardiovascular "event" - heart attacks and/or strokes - was almost double in patients who received the drug, compared to patients who took the placebo, according to a study out Feb. 15 on-line in The New England Journal of Medicine.

15 Feb 2005

Genetically engineered potatoes offer new hope in the fight against the Hepatitis B

Genetically engineered potatoes offer new hope in the fight against the Hepatitis B Virus (HBV), an acute sometimes fatal form of viral hepatitis caused by a DNA virus that persists in the blood serum and is transmitted by sexual contact or by transfusion or by ingestion of contaminated blood or other bodily fluids.

14 Feb 2005